Cenobamate
Sponsors
SK Life Science, Inc., Brigham and Women's Hospital, Ono Pharmaceutical Co. Ltd, Aziende Chimiche Riunite Angelini Francesco S.p.A
Conditions
Epilepsies, PartialEpilepsyEpilepsy, GeneralizedFocal Epilepsy With and Without Secondary GeneralizationFocal Onset SeizureFocal SeizureHealthyHealthy Volunteer
Early Phase 1
Phase 1
Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs As a Means of Predicting Drug-drug Interactions
CompletedNCT03234699
Start: 2017-02-22End: 2017-07-31Updated: 2024-09-19
A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users
CompletedNCT03509285
Start: 2017-03-08End: 2017-12-15Updated: 2024-11-07
Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
CompletedNCT04791553
Start: 2021-06-17End: 2023-08-11Updated: 2024-03-28
A Randomized, Open-label, Three-way Crossover Study to Evaluate the Relative Bioavailability of 200 Mg Cenobamate Administered Orally
CompletedNCT05572255
Start: 2022-09-27End: 2023-01-28Updated: 2024-09-19
Phase 2
Phase 3
Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures
CompletedNCT03678753
Start: 2018-09-21End: 2025-05-26Updated: 2025-07-09
Cenobamate Open-Label Extension Study for YKP3089C025
Enrolling by invitationNCT03961568
Start: 2019-08-13End: 2026-08-31Target: 145Updated: 2026-01-07
Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS
NCT04557085
Start: 2021-03-08End: 2025-03-31Target: 540Updated: 2023-10-10
ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures.
RecruitingNCT06579573
Start: 2022-07-12End: 2027-01-31Target: 15Updated: 2025-06-17